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The immune response has evolved to protect the host 
from a wide range of potentially pathogenic micro-
organisms, but parallel mechanisms to control over-
exuberant immune responses and prevent reactivity to 
self are required to limit host damage. Interleukin-10 
(IL-10) is an anti-inflammatory cytokine with a cru-
cial role in preventing inflammatory and autoimmune 
pathologies1–3. IL-10-deficient mice4 develop inflam-
matory bowel disease following colonization of the 
gut with particular microorganisms5 (BOX 1) and show 
other exaggerated inflammatory responses to micro-
bial challenge. Although the absence of IL-10 leads to 
better clearance of some pathogens with no enhanced 
immuno pathology 6,7, during other infections the 
absence of IL-10 can be accompanied by an immuno-
pathology that is detrimental to the host but does not 
necessarily affect the pathogen load3,8–11. This suggests 
that an absence of IL-10 is not always compensated by 
other regulatory mechanisms and thus that there is a 
non-redundant role for IL-10 in limiting inflammatory 
responses in vivo.
To inhibit inflammatory pathologies, IL-10 func-
tions at different stages of an immune response and 
possibly at different anatomical locations. IL-10 was 
initially described as a T helper 2 (TH2)-type cytokine12, 
but further evidence suggested that the production of 
IL-10 was associated with tolerant or regulatory T (TReg) 
cell responses3,13,14. It is now known that the expres-
sion of IL-10 is not specific to TH2 cells or TReg cells but 
instead that it is a much more broadly expressed cytokine 
(FIG. 1). IL-10 is expressed by many cells of the adap-
tive immune system, including TH1, TH2 and TH17 cell 
subsets, TReg cells, CD8+ T cells and B cells (reviewed in 
ReFs 3,10,11,14–16). It is also expressed by cells of the 
innate immune system, including dendritic cells (DCs), 
macrophages, mast cells, natural killer (NK) cells, eosino-
phils and neutrophils3 (FIG. 1). Thus, IL-10 production 
seems to be associated with many immune cells, affirming 
its crucial role as a feedback regulator of diverse immune 
responses, not only TH1 cell responses10,11 but also TH2 
cell responses to schistosome parasites17, Aspergillus spp.18 
and allergens19 (reviewed in ReF. 1).
Much is known about the function of IL-10. For 
example, the induction of the anti-inflammatory 
response mediated through the IL-10 receptor (IL-10R) 
and activation of signal transducer and activator of 
transcription 3 (STAT3) is reviewed in ReFs 3,20. By 
acting on DCs and macrophages, IL-10 inhibits the 
development of TH1-type responses (reviewed in ReF. 3) 
but also leads to the suppression of TH2 cell and aller-
gic responses (reviewed in ReF. 1). In addition to an 
autocrine inhibitory effect of IL-10 on macrophages 
and DCs, and because IL-10 can be produced by TH1, 
TH2 and TH17 cells, an additional feedback loop exists 
to limit the innate effector functions of macrophages 
and DCs and their subsequent activation of T cells. 
However, IL-10 enhances the differentiation of IL-10-
secreting TReg cells, thus providing a positive regula-
tory loop for its induction21 (reviewed in ReFs 1,14). 
In some situations, IL-10 also activates mast cells and 
enhances the functions of CD8+ T cells, NK cells and 
B cells (reviewed in ReFs 2,3), although these effects 
have yet to be tested in infection models.
So, IL-10 is a cytokine with important effects on the 
development of an immune response. An understanding 
of how IL10 expression is regulated in different innate 
*Microbiology and Infection 
Research Domain, Life and 
Health Sciences Research 
Institute (ICVS), School of 
Health Sciences, University of 
Minho, Campus de Gualtar, 
4710‑057 Braga, Portugal.
‡Division of Immunoregulation, 
Medical Research Council 
National Institute for Medical 
Research, The Ridgeway, 
Mill Hill, London NW7 1AA, 
UK.
Correspondence to A.O’G. 
e‑mail:  
aogarra@nimr.mrc.ac.uk
doi:10.1038/nri2711
Published online  
15 February 2010
The regulation of IL‑10 production by 
immune cells
Margarida Saraiva* and Anne O’Garra‡
Abstract | Interleukin‑10 (IL‑10), a cytokine with anti‑inflammatory properties, has a central 
role in infection by limiting the immune response to pathogens and thereby preventing 
damage to the host. Recently, an increasing interest in how IL10 expression is regulated in 
different immune cells has revealed some of the molecular mechanisms involved at the 
levels of signal transduction, epigenetics, transcription factor binding and gene activation. 
Understanding the specific molecular events that regulate the production of IL‑10 will 
help to answer the remaining questions that are important for the design of new strategies 
of immune intervention.
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Chromatin 
Composed of nucleosomes, 
this is the basic repeating unit 
of eukaryotic genomes. 
Nucleosomes consist of 146 
base pairs of DNA wound 
around an octamer of histone 
proteins.
Plasmacytoid DC
A DC that lacks myeloid 
markers such as CD11c and 
CD33 but expresses high levels 
of HLA-DR and CD123. These 
cells produce high levels of 
type I interferons in response 
to viral infection.
and adaptive immune cells is therefore of importance 
for the development of immune intervention strate-
gies in various pathologies. Several layers of regula-
tion of IL-10 expression exist, and this is a main focus 
of this Review. First, regulation of IL-10 production 
involves changes in the chromatin structure at the 
IL10 locus. A second layer of regulation involves 
the enhancement or silencing of IL10 transcription and 
is controlled by specific transcription factors activated by 
discrete signal-transduction pathways. In addition, post- 
transcriptional mechanisms exist. Many of the molecu-
lar events leading to IL10 expression are common to 
various IL-10-producing immune cells. However, there 
are also cell-specific signals and molecular mechanisms 
that allow IL-10 production by particular immune cells 
and not by others.
In this Review, we discuss our current understand-
ing of the regulation of IL10 expression at the molecular 
level in different cell types, from signal transduction 
pathways to epigenetic regulation and the activation of 
specific transcription factors involved in IL-10 produc-
tion. Throughout, we highlight the common and distinct 
mechanisms of IL-10 regulation that exist in different 
IL-10-producing immune cells.
IL‑10 production by immune cells
Induction by pathogen-derived products. pathogen 
activation of DCs and macrophages involves the rec-
ognition of pathogen-derived products by pattern 
recognition receptors (pRRs), which triggers the expres-
sion of cytokines and other factors22. Both macro-
phages23–27 and DCs26,28–33 can express IL-10 in vitro 
following activation of specific pRRs (FIG. 2a). In addi-
tion, DCs31,34, macrophages35 and neutrophils36 have been 
reported to express IL-10 in vivo.
It has been suggested that Toll-like receptor 2 (TLR2) 
agonists are specialized in inducing IL-10 expression 
by antigen-presenting cells (ApCs)29,30,37,38. For exam-
ple, TLR2 signalling is crucial for the induction of 
IL-10 production by macrophages (M. Teixeira-Coelho, 
J. Carmona, A. G. Castro and M.S., unpublished obser-
vations) or by DCs39 stimulated with Mycobacterium 
tuberculosis or with lipopeptides and the Lcrv antigen 
of Yersinia pestis40. IL-10 production by macrophages 
following pneumoccocal cell wall stimulation mainly 
depends on TLR2; however, in this case a role for 
nucleotide-binding oligomerization domain 2 (NoD2) 
signalling, independent of TLR2, has also been 
described41. Significant amounts of IL-10 are also 
produced by macrophages and myeloid DCs following 
stimulation with TLR4 and TLR9 ligands26. of note, 
IL-10 production following TLR3 stimulation was only 
observed in macrophages26. Interestingly, activation 
of macrophages through TLRs results in high levels of 
IL-10 production, whereas myeloid DCs only produce 
intermediate amounts and plasmacytoid DCs (pDCs) do 
not produce detectable levels of IL-10 (ReF. 26) (FIG. 1). 
In addition, IL-10 can be induced by TLR-independent 
stimuli, such as the C-type lectins DC-specific ICAM3-
grabbing non-integrin (DC-SIGN; also known as 
CLeC4M)33 and dectin 1 (also known as CLeC7A)32 
(FIG. 2a). Ligation of CD40 enhances IL-10 production by 
TLR-stimulated28 or dectin 1-stimulated DCs32 and liga-
tion of Fc receptors (FcRs) enhances IL-10 production 
by TLR-stimulated macrophages25.
Signalling pathways for innate IL-10 production. 
Following TLR ligation, signalling cascades are activated 
through Toll/IL-1 receptor (TIR)-domain-containing 
adaptor molecules, such as myeloid differentiation pri-
mary-response protein 88 (MYD88) and TIR-domain-
containing adaptor protein inducing IFNβ (TRIF; also 
known as TICAM1), leading to the production of IL-10 
and pro-inflammatory cytokines26,30,42. TLR signalling 
through MYD88 leads to the activation of mitogen- 
activated protein kinases (MApKs) and nuclear factor-κB 
(NF-κB)43 (FIG. 2a).
Additional signals that are required for IL-10 pro-
duction by macrophages have also been reported. of 
note, optimal lipopolysaccharide (LpS)-induced IL-10 
production by macrophages requires both the activa-
tion of the TRIF- and MYD88-dependent pathways26,27 
and the production of and signalling by type I inter-
ferons (IFNs)27. This secondary induction of IL-10 by 
type I IFNs has important implications for the use 
of type I IFNs as potential anti-inflammatory drugs. 
Moreover, this study is in line with the observation 
that TNFR-associated factor 3 (TRAF3), an important 
component of the type I IFN production pathway, is 
also involved in LpS-induced upregulation of IL-10 
expression42.
The MApK cascade is composed of three major 
groups of kinases: extracellular signal-regulated kinases 
(eRKs) (comprising eRK1 (also known as MApK3) 
and eRK2 (also known as MApK1), which are collec-
tively referred to here as eRK); JuN N-terminal kinases 
 Box 1 | IL‑10 expression and gut homeostasis
The intestine is continuously exposed to bacterial flora, dietary antigens and 
potential pathogens. To prevent chronic intestinal inflammation, various regulatory 
lymphocyte populations keep the immune response in check. These populations  
use several regulatory mechanisms, the best characterized of which involves 
interleukin-10 (IL-10) and transforming growth factor-β (TGFβ)15,155. IL-10- or IL-10 
receptor-deficient mice do not develop severe autoimmune disorders but develop 
colitis in the presence of microorganisms4,156. Many studies unequivocally identify 
CD4+ T cell-derived IL-10 as a key mediator of intestinal immune homeostasis157–161. 
Coeliac disease and inflammatory bowel disease (IBD) are the most common causes 
of non-infectious intestinal inflammation in humans, with recent reports identifying 
IL10 as a susceptibility locus for the development of IBD162. Polymorphisms in 
nucleotide-binding oligomerization domain 2 (NOD2) have also been associated 
with IBD in humans163, which is interesting considering that NOD2 has been 
associated with IL-10 production41. IL-10 seems to function not directly on T cells, 
but instead on myeloid cell populations in a similar manner to that observed in the 
immune response to pathogens3. In vivo IL-10 production by forkhead box P3 
(FOXP3+) regulatory T (T
Reg
) cells and FOXP3– regulatory T cells in the gut seems to 
be mediated by TGFβ, independently of endogenous IL-10 (ReF. 97). This IL-10 
independence is in contrast to that reported in vitro for human IL-10-producing 
regulatory T cells14. Retinoic acid was identified as a cofactor for TGFβ in the 
induction of FOXP3+ T
Reg
 cells164–166, although retinoic acid itself downregulates the 
expression of IL-10 by inducible FOXP3– regulatory T cells92. Although the exact 
mechanisms of IL-10 induction in the intestine remain elusive, the protective role 
of intestinal T
Reg
 cells mostly depends on their expression of IL-10, suggesting that 
local IL-10 expression might be a therapy for IBD2.
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(JNKs) (comprising JNK1 (also known as MApK8) 
and JNK2 (also known as MApK9)); and p38 (ReF. 44). 
Following TLR stimulation, activation of eRK modulates 
IL-10 expression30,45–47, and in the presence of chemi-
cal inhibitors of eRK30,45,47 or in eRK-deficient cells46 
IL-10 production by TLR-activated DCs is decreased. 
Furthermore, the differences in IL-10 production by 
macrophages, myeloid DCs and pDCs have been shown 
to correlate with the strength of eRK activation in each 
of these cell types47. Following TLR stimulation, eRK is 
most highly activated in macrophages, with lower activa-
tion of eRK in myeloid DCs and the lowest amount of 
activated eRK in pDCs47 (FIG. 1).
Further studies using cells deficient for tumour 
progression locus 2 (TpL2) or NF-κB1 (also known as 
p105) support the role of eRK in the induction of IL-10. 
TpL2 is an upstream activator of eRK and, following 
TLR stimulation, TpL2 dissociates from the TpL2–
NF-κB1 complex and activates eRK. In the absence 
of NF-κB1, TpL2 is rapidly degraded in the cell and, 
as a consequence, eRK activation by TpL2 is compro-
mised48. In TpL2-deficient macrophages and myeloid 
DCs the amounts of TLR-induced IL-10 were lower 
than in wild-type cells owing to the absence of eRK 
activation47. Similarly, NF-κB1-deficient macrophages 
have lower levels of IL-10 expression than control cells 
Figure 1 | Interleukin‑10 expression in the immune system. a | Interleukin‑10 (IL‑10) is expressed by macrophages  
and myeloid dendritic cells (DCs), but not by plasmacytoid DCs, in response to microbial products. The extracellular 
signal‑regulated kinase 1 (ERK1) and ERK2 (which are collectively referred to here as ERK) pathway is one of the signalling 
cascades that is activated in these cells that results in IL‑10 expression. For other immune cells, such as B cells, mast cells 
and eosinophils, the exact signalling pathways that lead to IL‑10 production remain elusive. b | In T helper (T
H
) cells, the 
expression of IL‑10 is accompanied by the expression of the signature cytokines for each subset, with the exception of 
regulatory T (T
Reg
) cells, which normally lose the capacity to express other cytokines. Although the differentiation of T
H
 
cells from naive CD4+ T cells requires T cell receptor triggering and the activation of distinct signal transducer and 
activator of transcription (STAT) pathways, activation of the ERK pathway is a common requirement for IL‑10 expression by 
these cells. High doses of antigen presented by DCs to naive T cells or IL‑12 favours the development of T
H
1 cells, which 
produce interferon‑γ (IFNγ). IL‑10‑producing T
H
1 cells require high antigen dose and IL‑12 and STAT4 signalling for the 
expression of maximum levels of IL‑10 following re‑stimulation. In T
H
2 cells, IL‑4 and STAT6 signalling pathways are 
required for IL‑10 expression. Induction of IL‑10‑producing T
H
17 cells is not well understood, but transforming growth 
factor‑β (TGFβ), IL‑6, IL‑21 and/or IL‑27 and STAT3 signalling are likely to be involved. c | TGFβ can induce the production 
of IL‑10 by forkhead box P3 (FOXP3)+ T
Reg
 cells and this cytokine can also promote the development of IL‑10‑producing 
FOXP3– regulatory T cells from naive T cells. Conversely, FOXP3+ IL‑10‑producing T
Reg
 cells can differentiate from naive 
T cells in vitro in the presence of TGFβ and retinoic acid. 
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following TLR activation49. IL-10 expression was only 
partially restored following rescue of eRK activation in 
these cells49, indicating that NF-κB-mediated regulation 
of IL-10 production involves both eRK-dependent and 
eRK-independent mechanisms, as had been suggested 
by previous studies50,51. Furthermore, pathogen trigger-
ing of DC-SIGN in human DCs resulted in the activation 
of RAF1, leading to acetylation of the NF-κB p65 subunit 
and to prolonged and increased IL10 transcription52. This 
effect was only observed after TLR-dependent NF-κB 
activation, suggesting that activation of DC-SIGN can 
modulate TLR-induced IL-10 production52.
The regulation of IL-10 production in response to 
dectin 1 ligation depends on spleen tyrosine kinase 
(SYK)32. SYK is recruited to phosphorylated dectin 1 
(ReF. 53) and initiates a signalling cascade that induces 
IL-2 and IL-10 production32. IL-10 production down-
stream of dectin 1 also requires signalling through the 
eRK pathway, despite being independent of TLR activa-
tion54 (FIG. 2a). Furthermore, IL-10 production by FcR 
ligation in the presence of TLR signals in macrophages 
can also lead to eRK activation55. Therefore, eRK activa-
tion is common to several signalling pathways upstream 
of IL10 in macrophages and DCs.
IL-10 expression can also be compromised by inhibi-
tion of p38 signalling in LpS- or CpG-activated macro-
phages45,56–58, primary DCs59 and human peripheral 
blood monocytes60. primary cells lacking the p38 regula-
tor dual-specificity protein phosphatase 1 (DuSp1) have 
prolonged p38 activation and increased levels of IL-10 
expression following TLR stimulation61–63. This could be 
reversed by chemically inhibiting p38 signalling61,62.
Interestingly, abrogation of either eRK or p38 activa-
tion leads to a reduction, but not abrogation, of IL-10 
expression, which suggests that these two pathways might 
cooperate in TLR-induced IL-10 production. Supporting 
this hypothesis, inhibition of both the eRK and p38 
pathways in LpS- or CpG-stimulated macrophages leads 
to an almost complete abrogation of IL-10 production 
(A.o’G., unpublished observations). Furthermore, defi-
ciency of mitogen- and stress-activated protein kinase 1 
(MSK1; also known as RpS6Kα5) and MSK2 (also known 
as RpS6Kα4), which are activated downstream of the p38 
and eRK pathways, correlated with a loss of IL-10 expres-
sion by LpS-stimulated macrophages64.
The production of IL-10 by macrophages and DCs 
is also regulated by the activation of certain inhibitory 
pathways. eRK- and p38-dependent IL-10 production 
is inhibited by IFNγ38 (FIG. 2b). In addition to directly 
blocking TLR-induced MApK activation, IFNγ induces 
the release of glycogen synthase kinase 3 (GSK3) by 
antagonizing phosphoinositide 3-kinase (pI3K)–AKT 
activation. This leads to inhibition of TLR-induced 
IL-10 production by suppressing the binding of acti-
vator protein 1 (Ap1) to the Il10 promoter38. Another 
negative feedback loop controlling IL-10 production by 
macrophages is mediated by IL-10 itself. IL-10 induces 
the expression of DuSp1, which negatively regulates p38 
phosphorylation and thus limits IL-10 production65. By 
contrast, IL-10 positively feeds back to upregulate Tpl2 
expression66, thus providing a positive amplification 
Figure 2 | Signals that induce interleukin‑10 expression by cells of the innate immune 
response. a | The expression of interleukin‑10 (IL‑10) can be induced by Toll‑like receptor 
(TLR) or non‑TLR signalling in macrophages and myeloid dendritic cells (DCs). Activation of 
TLRs and their adaptor molecules — myeloid differentiation prima y‑r spon e protein 88 
(MYD88) and TIR‑domain‑containing adaptor protein inducing IFNβ (TRIF) — results in  
the activation of the extracellular signal‑regulated kinase 1 (ERK1) and ERK2 (which are 
collectively referred to here as ERK), p38 and nuclear factor‑κB (NF‑κB) pathways. 
Activation of these pathways results in the induction of IL‑10 expression, in addition to 
pro‑inflammatory cytokines. In myeloid DCs, non‑TLR signals through DC‑specific 
ICAM3‑grabbing non‑integrin (DC‑SIGN) and RAF1 can augment TLR2‑induced IL‑10 
production. Furthermore, activation of dectin 1 and the signalling molecules spleen 
tyrosine kinase (SYK) and ERK results in IL‑10 production. In macrophages, a role for 
nucleotide‑binding oligomerization domain 2 (NOD2) signalling in IL‑10 induction, in 
crosstalk with TLR2, has been described. b | Positive and negative feedback loops for IL‑10 
regulation in macrophages. The p38 and ERK pathways leading to IL‑10 expression by 
macrophages are tightly controlled by interferon‑γ (IFNγ) and IL‑10 itself. IL‑10 feeds back 
to induce the expression of dual‑specificity protein phosphatase 1 (DUSP1), which 
negatively regulates p38 phosphorylation and thus limits IL‑10 production. IL‑10 can also 
positively feed back to upregulate tumour progression locus 2 (TPL2) expression, thus 
providing a positive amplification loop for its own production. In addition, IFNγ can also 
interfere with the phosphoinositide 3‑kinase (PI3K)–AKT pathway, releasing glycogen 
synthase kinase 3 (GSK3). As GSK3 normally blocks IL‑10 expression by acting on the 
transcription factors cAMP response element‑binding protein (CREB) and activator 
protein 1 (AP1), IL‑10 production is inhibited by IFNγ through its effects on PI3K. IL‑10R, 
IL‑10 receptor; MEK, MAPK/ERK1 kinase; MSK, mitogen‑ and stress‑activated protein 
kinase; RIP2, receptor‑interacting protein 2; STAT3, signal transducer and activator of 
transcription 3; TRAF3, TNFR‑associated factor 3. 
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Notch 
A signalling system  
comprising highly conserved 
transmembrane receptors that 
regulate cell fate choice in the 
development of many cell 
lineages. Therefore, they are 
crucial in the regulation of 
embryonic differentiation  
and development.
loop for its own production. IL-10 was also described 
to induce its own transcription in human monocytes in 
a STAT3-dependent manner67, which may result from 
its upregulation of TpL2 and thus eRK activation66. 
However, the mechanisms dictating the balance between 
IL-10-mediated negative and positive feedback loops are 
currently not clear. Furthermore, the inhibition of IL-10 
production by NK cell- or T cell-derived IFNγ in vivo 
will also influence these loops.
various pathogen-derived products induce IL10 
expression by macrophages and DCs through the acti-
vation of signalling cascades that, although common 
to various stimuli and different cells, have distinct 
thresholds of activation depending on the cell type, 
which reflect the distinct amounts of IL-10 produced 
by these cells.
IL-10 production by TH cells. IL-10 production was first 
described in TH2 cells12,68, where its expression accom-
panies that of the TH2-type cytokines IL-4, IL-5 and 
IL-13. TH1 cells can also be induced to produce IL-10, 
but, in contrast to TH2 cells, only under certain condi-
tions10,11,15,69–76 (FIG. 1). Furthermore, TH17 cells have 
recently been shown to produce IL-10 (ReFs 72, 77–79). 
The fact that TH1, TH2 and TH17 cells are dependent on 
DC- and macrophage-derived factors that are downregu-
lated by IL-10, but these subsets can all be induced to 
produce IL-10, is indicative of a negative feedback loop 
that ensures that effector T cell responses do not result 
in immunopathology. It is of interest to note that IL-9-
producing TH cells, which have recently been suggested to 
be a unique TH cell subset (TH9 cells), also express IL-10 
(ReF. 80).
Molecular signals for IL-10 induction in TH cells. 
IL-10-inducing signalling cascades have been studied 
less thoroughly in TH cells than in macrophages and 
DCs. IL-10-producing TH1 cells have been described 
in infectious diseases, human CD4+ T cell clones and 
mouse CD4+ T cells. TH1 cells that produce both IFNγ 
and IL-10 can be generated by inducing T cells to pro-
liferate with high levels of antigen-specific or polyclonal 
stimulation in the presence of IL-12 (ReFs 10,11,69,70) 
(FIG. 1). However, until recently the signals that determine 
whether TH1 cells produce IL-10 were not known. Strong 
T cell receptor (TCR) triggering (high antigen dose)71 and 
endogenous IL-12 have now been shown to be essential 
for the differentiation of IL-10-producing TH1 cells, as 
well as for maximal expression of IL-10 following re-
stimulation of these cells72. IL-10 induction in TH1 cells 
is STAT4 and eRK dependent72 (FIG. 1). Notch signalling 
can also induce IL-10 expression by TH1 cells, a process 
that requires STAT4 (ReF. 81). In TH2 cells, IL-10 produc-
tion seems to be regulated by the main TH2 type-associ-
ated signalling pathways and transcription factors: IL-4, 
STAT6 and GATA binding protein 3 (GATA3)82–84. IL-10 
expression by TH17 cells seems to occur in a STAT3- and, 
in some cases, STAT1-dependent manner79,85 (FIG. 1). 
Thus, to induce IL-10 expression, TH1, TH2 and TH17 
cells require the same signals needed for each TH cell 
differentiation programme. However, IL-10 production 
by all these subsets requires eRK activation72, indicating 
that a common molecular mechanism exists for IL-10 
production by TH cells. Chemical inhibition of the p38 
signalling pathway did not compromise the production 
of IL-10 by TH1, TH2 or TH17 cells72, suggesting that in TH 
cells the role of eRK is dominant over that of p38. This 
observation is in contrast to a joint role for eRK and p38 
in IL-10 induction in macrophages and DCs.
IL-21 can enhance IL-10 expression by CD4+ T cells 
in the context of different stimuli86, and IL-27 enhances 
IL-10 expression by TH1, TH2 and TH17 cells78,79,85,87,88. 
By contrast, IL-27 attenuates TLR-induced IL10 expres-
sion by human monocytes89. of interest, it has recently 
been shown that both IL-21 and IL-27 induce eRK 
activation90,91, but it is currently not clear whether this 
explains the ability of these cytokines to upregulate IL-10 
production. Also, both IL-21 and IL-27, in addition to 
eRK, activate STAT3, which seems to be involved in 
IL-27-mediated IL-10 upregulation by T cells79.
undoubtedly, all T cell subsets can produce IL-10, as 
well as their hallmark cytokines, following TCR trigger-
ing, but this depends on the environmental context and 
strength of stimulus10,11,69–73,92–94. 
IL-10 and regulatory T cells. TReg cells, which are char-
acterized by their specific expression of the transcrip-
tion factor forkhead box p3 (FoXp3), do not express 
IL-10 following stimulation directly after ex vivo isola-
tion95,96, unless isolated from the gut97 (BOX 1). Although 
FoXp3+ TReg cells inhibit naive T cell proliferation in vitro 
independently of IL-10, in some cases, TReg cells mediate 
their regulatory function in vivo through IL-10 (reviewed 
in ReFs 1,14,16,98–100). Therefore, TReg cells must receive 
signals in vivo to induce the expression of this suppressive 
cytokine. Both IL-2 and IL-4 have been shown to induce 
IL-10 production after culture of TReg cells in vitro101,102. 
However, in these studies, the TReg cell population analysed 
might have contained some effector T cells and therefore 
the source of IL-10 cannot be confirmed. So far the signals 
that induce IL-10 expression by FoXp3+ TReg cells remain 
elusive, although transforming growth factor β (TGFβ) 
has been shown to be required in vivo97 (FIG. 1).
Several populations of antigen-driven FoXp3– 
IL-10-producing T cells with regulatory activity that are 
distinct from naturally occurring TReg cells have been 
described (reviewed in ReFs 1,2,13,14). These cells pro-
duce IL-10, but not IL-2, IL-4 or IFNγ, and can be gen-
erated in vitro using various stimuli, such as cytokine 
cocktails (TGFβ, IL-10 and IFNα) or immunosuppres-
sive drugs (vitamin D3 and dexamethasone)1,2,13,14,21, or 
in vivo by repeated stimulation with soluble antigen71,103. 
Additional signals for IL-10 expression by these FoXp3– 
regulatory T cells include co-stimulation through CD2 
or CD46 and stimulation with type I IFNs or with 
immature DCs (reviewed in ReFs 1,14,104). Signals 
delivered through inducible T cell co-stimulator (ICoS) 
have also been suggested to induce IL-10 expression by 
FoXp3– regulatory T cells105,106; a similar effect has been 
observed in TH2 cells107,108, suggesting that, although it 
is involved in the induction of IL-10, ICoS is not a cell 
type-specific inducer of IL-10.
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DNaseI hypersensitive sites
sites of nuclease sensitivity in 
the nuclei on exposure of cells 
to limiting concentrations of 
DNaseI. The digested regions 
of DNA correspond to sites of 
open DNA, which might be 
factor-binding sites or areas of 
altered nucleosome 
conformation.
Chromatin remodelling 
Alterations that are induced  
in chromatin by enzymes  
that modify the extent of 
acetylation, methylation or 
other covalent modifications  
of histones.
Acetylation 
A post-translational 
modification of chromatin 
components, particularly 
histones. It correlates with 
actively transcribed chromatin.
It will be of interest to determine whether IL-10-
producing FoXp3– regulatory T cells differentiate directly 
from naive T cells or are derived from TH1, TH2, TH9 
or TH17 cells that have lost expression of their effec-
tor T cell cytokines but have maintained IL-10 expres-
sion. It is possible that FoXp3– regulatory T cells that 
only make IL-10 have originally differentiated along a 
TH1 cell pathway through repeated high-level antigenic 
stimulation, which results in IL-10 production and ulti-
mately in the downregulation of TH1 cell production 
of IFNγ by feedback inhibition of IL-12 production by 
DCs and macrophages71.
Additional cell types that produce IL-10. In addition 
to macrophages, DCs and CD4+ T cells, other cells of 
the immune system are also known to express IL-10. 
CD8+ T cells express IL-10 following TCR activation 
or interaction with CD40 ligand expressed by activated 
pDCs109–111, and this IL-10 production can be enhanced 
by IL-21 (ReF. 86). Stimulation of B cells with auto-
antigens, TLR4 and TLR9 ligands or vitamin D3 also 
leads to IL-10 production112–117. Finally, mast cells can 
express IL-10 following TLR4 activation or during skin 
allergic or damage responses1,118,119. Recently, neutro-
phils were reported to produce IL-10 in response to TLR 
and C-type lectin co-activation through MYD88 and 
SYK, respectively36. These IL-10-producing neutrophils 
were shown to be recruited to the lung during myco-
bacterial infections and to regulate local immune inflam-
matory responses36. It is currently not clear whether 
the molecular mechanisms required for the induction 
of IL-10 by these cells are regulated by the common 
factors that regulate IL-10 production by TH cells, 
macrophages and DCs.
understanding the molecular pathways leading 
to IL-10 production by different immune cells might 
provide valuable information on possible targets for 
IL-10 manipulation. This will be useful in the design 
of intervention strategies to modulate IL-10 production 
and ultimately the immune response.
Transcription factors that regulate IL‑10
Activating the IL10 promoter. The structure of the human 
and mouse IL10 promoters is similar and both contain a 
TATA box and a CCAAT box (CCAGT in mice). The 
human and mouse IL10 promoters have a high level of 
homology, particularly around certain putative binding 
sites for transcription factors. However, the presence of a 
conserved putative binding site in a gene promoter does 
not guarantee transcription factor binding.
In addition to epigenetic control (BOX 2), the expression 
of IL10 depends on transcription factor binding. The tran-
scription factors specific protein 1 (Sp1)120, Sp3 (ReF. 121), 
CCAAT/enhancer binding protein-β (C/eBpβ)122,123, IFN-
regulatory factor 1 (IRF1) and STAT3 (ReF. 124) have been 
proposed to bind to and transactivate IL10 in macrophage 
and T cell lines of mouse or human origin (FIGs 3, 4). Also, 
binding of the NF-κB p50 subunit to the IL10 promoter in 
a human T cell lymphoma cell line has been described125. 
Moreover, some of these findings depend on the cell type 
and on the stimulus used. For example, whereas one study 
indicates that IL10 promoter activity relies on an Sp1 site 
located between positions –636 and –631 relative to the 
initiation site56, another report shows that IL10 promoter 
activity relies on the C/eBp5 motif positioned between 
the TATA box and the translation start point122. Although 
both studies were carried out using the human pro- 
monocytic cell line THp1, the type of stimulation was 
different (LpS versus cyclic AMp (cAMp), respectively), 
which might account for the differences observed.
Studies using mouse primary cells have shown that 
homodimers of NF-κB p50 bind to the proximal Il10 
promoter, activating Il10 transcription in primary mac-
rophages126, and p50-deficient macrophages have an 
impaired expression of IL-10 following LpS stimulation 
compared with wild-type macrophages126. Furthermore, 
IL-10 induction in response to double-stranded RNA 
stimulation and viral infection of mouse macrophages 
was described to be protein kinase R (pKR) depend-
ent and to be regulated by binding of NF-κB to a dis-
tinct site in the Il10 promoter127. In addition to NF-κB, 
a role for C/eBpβ in cAMp-mediated IL-10 produc-
tion was confirmed in mouse primary macrophages; 
nuclear accumulation and DNA binding of C/eBpβ was 
involved in IL-10 production in response to adenosine 
and Escherichia coli infection, and C/eBpβ-deficient 
macrophages failed to produce IL-10 (ReF. 128).
Recently, two cofactors of the homeobox (HoX) fam-
ily, pre-B-cell leukaemia transcription factor 1 (pBX1) 
and pBX-regulating protein 1 (pRep1), were implicated 
in inducing IL-10 expression by mouse macrophages129. 
In this study, the expression of IL-10 was triggered by 
the interaction of macrophages with apoptotic cells 
and depended on p38; in human cells, transcription 
of IL10 cells was mediated by the binding of pBX1 and 
 Box 2 | Epigenetic control of IL10 expression
Several studies suggest that the expression of interleukin-10 (IL-10) is regulated by 
changes in the structure of the chromatin at the IL10 locus51,133–135 (FIG. 3). Various 
DNaseI hypersensitive sites (HSSs) were found in the mouse Il10 locus, most of which are 
common to IL-10-producing T cells, macrophages and dendritic cells (DCs). However, a 
macrophage-specific regulatory element (HSS–4.5), which is absent in T cells, was also 
found51. Although chromatin remodelling seems to be one of the initial events leading to 
IL10 expression, additional signals are required to allow high rates of IL10 transcription. 
Epigenetic imprinting of the Il10 locus in mice, as measured by histone acetylation, was 
observed in high-IL-10-producing T helper 2 (T
H
2 cells)84 and macrophages51 but not in 
low-IL-10-producing T
H
1 cells84, despite the open conformation of the IL10 locus 
observed for all these cell types. In macrophages, the histones at the Il10 locus were also 
reported to be hyperphosphorylated55,167. Furthermore, by interacting with the distal 
segment of the IL10 promoter, histone deacetylase 11 negatively regulated the 
expression of this cytokine in human and mouse antigen-presenting cells168.
Several studies have identified GATA binding protein 3 (GATA3) as a possible 
initiator of chromatin remodelling and histone acetylation of the Il10 locus in 
mice83,133. However, as GATA3 is only expressed by T
H
2 cells and not in other 
IL-10-producing T
H
 cells, macrophages or DCs, other mechanisms must operate in 
these cells to induce chromatin remodelling at the Il10 locus. A clue may come 
from the finding that, in macrophages, remodelling of the Il10 locus occurs following 
TLR stimulation51 or Fc receptor binding in an extracellular signal-regulated kinase 
(ERK)-dependent manner55.
Overall, analysis of the chromatin conformation at the IL10 locus may help to explain 
the different levels of IL10 expression and the different factors involved in this 
expression by different cell types, although many questions still remain unanswered.
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pRep1 to the apoptotic cell-response element (ACRe) in 
the IL10 promoter129. The transcription factors cAMp-
responsive-element-binding protein (CReB) and acti-
vating transcription factor 1 (ATF1) have been shown 
to be activated by MSKs in LpS-stimulated mouse 
macrophages and to bind to the Il10 promoter, thus sug-
gesting a direct effect of the kinases MSK1 and MSK2 in 
the regulation of IL-10 induction64 (FIG. 2b). There is also 
evidence for TGFβ1-induced SMAD4 binding to and 
activating the Il10 promoter in mouse TH1 cells130; 
however, it is worth noting that TGFβ1 inhibits the 
development of TH1 and TH2 cells in vitro and thus their 
production of IL-10 (ReF. 72).
The transcription factor GATA3 was shown to be a 
master regulator of IL-10 expression in mouse TH2 cells by 
binding to and initiating changes in the chromatin struc-
ture at the Il10 locus83,84. Although one of the binding sites 
for GATA3 is located in the Il10 promoter, GATA3 alone 
does not transactivate the Il10 promoter83. GATA3 may 
thus be responsible for remodelling the Il10 locus in TH2 
cells, with other factors being necessary to induce high lev-
els of IL-10 expression in other cell types such as TH1 cells 
that do not express GATA3 (ReFs 69,72).
originally described as a TH2 cell-specific factor131, 
the transcription factor MAF has been shown to bind 
to the Il10 promoter and have a role in the transcriptional 
regulation of IL-10 in mouse macrophages stimulated 
with LpS and IL-4, although MAF alone is not sufficient 
to induce Il10 expression in these cells132. other recent 
reports have also implicated MAF in the expression of 
IL-10 by TH17 cells, showing binding of this transcrip-
tion factor to MAF recognition elements in the Il10 
promoter85, and in the differentiation of IL-10-producing 
FoXp3– regulatory T cells88. Finally, MAF expression is 
also detectable in TH1, TH2 and TH17 cells, correlating 
with IL-10 production, and MAF expression depends 
on eRK activation in TH1 and TH17 cells, similar to 
IL-10 expression72. Taken together, these reports sug-
gest that MAF may be a universal transcription factor 
for the regulation of IL-10 production, important in all 
IL-10-producing cells of both the innate and the adaptive 
immune systems.
As discussed, various transcription factors have been 
described to bind to and activate the IL10 promoter 
(FIGs 3, 4). The activity of one transcription factor or 
another to regulate IL10 expression seems to depend on 
the cell type and the type of stimuli. Furthermore, multi-
ple studies suggest that IL-10 is not regulated in a simple 
and linear manner, which is in accord with its function 
to keep diverse immune responses in check.
Enhancing IL10 transcription. Following the description 
of several distal regulatory elements in IL1051,133–135 (FIG. 3), 
the search for transcription factors with a role in regulat-
ing IL10 expression has been expanded to those that bind 
regions of the locus outside of the promoter region.
Figure 3 | molecular regulation of interleukin‑10 expression: the interleukin‑10 locus and promoter. The mouse 
interleukin‑10 (Il10) locus (top panel) and Il10 promoter (bottom panel) are represented here. Several DNaseI hypersensitive 
sites (HSSs), and their relative position to the Il10 starting site (+1), are indicated. Most of these HSSs are common to all cells, 
although some cellular specificity is also observed. Two of these sites (HSS–4.5 and HSS+6.45) have been studied in more detail, 
and their role in Il10 regulation has been described. HSS–4.5 contains hyperacetylated histones and binds nuclear factor‑κB 
(NF‑κB) in macrophages, whereas HSS+6.45 binds JUN proteins in T helper 2 (T
H
2) cells. Both HSS–4.5 and HSS+6.45 were 
shown to enhance the Il10 promoter activity in reporter assays. The biological role for the other HSSs needs to be further 
clarified. The proximal elements that regulate the expression of IL‑10, including the Il10 promoter, have been well studied. 
Several transcription factors have been shown to bind to the Il10 promoter and to enhance Il10 transcription in various cell 
types. In T
H
2 cells, GATA binding protein 3 (GATA3) functions as a master regulator for Il10 expression by binding to sites in the 
Il10 locus (including to the promoter) and inducing locus remodelling. Also represented are putative signal transducer and 
activator of transcription (STAT) binding sites in the mouse Il10 promoter. ATF1, activating transcription factor 1; C/EBPβ, 
CCAAT/enhancer binding protein‑β; CREB, cAMP‑responsive‑element‑binding protein; DC, dendritic cell; Enh, enhancer; 
GATA3, GATA binding protein 3; SMAD4, mothers against decapentaplegic homologue 4; SP, specific protein.
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The NF-κB p65 subunit binds to a newly described 
κB site located 4.5 kb upstream of the Il10 start site 
and has a role in enhancing IL-10 expression by LpS-
stimulated mouse macrophages51 (FIG. 3). This is in 
keeping with a report that mice deficient for inhibi-
tor of NF-κB kinase 2 (IKK2) show a defect in IL-10 
production in LpS-stimulated macrophages50. This 
κB site is exposed in IL-10-producing LpS-, CpG- or 
zymosan A-stimulated mouse macrophages and DCs 
but is absent in T cells51. This suggests that different 
molecular mechanisms might regulate the expression 
of Il10 in the innate versus adaptive immune systems 
and that the production of IL-10 by innate immune cells 
might be subject to additional regulation, as it is the first 
checkpoint for the initiation of immune responses and 
determines the class of the resulting adaptive immune 
response. of interest, however, is that eRK signalling is 
required for optimal IL-10 induction in macrophages, 
DCs and TH cell subsets, which questions whether 
transcription factors that are required for IL-10 induc-
tion in DCs and macrophages may also have a role in 
inducing IL-10 in T cells. one of the transcription fac-
tors implicated in TLR-induced IL-10 expression in 
mouse macrophages and DCs, by the activation of eRK, 
is FoS, the expression of which is strongly induced by 
high levels of eRK activation29,30,47.
Studies have suggested there is a role for JuN proteins 
in regulating Il10 in mouse TH2 cells, but not TH1 cells, 
through binding to a regulatory element located ~6.45 kb 
downstream of the Il10 start site133,134 (FIG. 3). This find-
ing supports our suggestion that alternative mechanisms 
probably operate to regulate Il10 induction in TH1 and 
TH2 cells and possibly in other TH cell subsets, although 
common factors, such as eRK and MAF, are required for 
Il10 induction in various cell types.
Although there are no data so far to show direct 
binding of the various STATs to the IL10 locus, an 
increasing amount of evidence suggests a role for the 
STAT proteins in regulating the induction of IL-10 
expression in both primary macrophages and T cells. 
In mouse T cells, the induction of IL-10 by IL-27 
seems to depend on both STAT1 (ReFs 79,87) and 
STAT3 (ReFs 79,85), and STAT3 is also involved in IL-6-
induced IL-10 expression79. By contrast, a recent study 
on human monocytes describes an inhibitory role for 
IL-27 on IL-10 production through STAT1 (ReF. 89). In 
addition, as STAT3 is required for TH17 cell differen-
tiation, this transcription factor may have an indirect 
role in IL-27-mediated induction of IL-10 by TH17 
cells by modulating TH17 cell differentiation. Another 
study suggests that IL-10 induces its own expression 
by human monocyte-derived macrophages in an 
autocrine manner through the activation of STAT3 
(ReF. 67). In this study, activation of the IL10 promoter 
depended on the integrity of the STAT3-binding site. 
Considering the data from human cell lines that show 
binding of STAT3 to the IL10 promoter124, it is pos-
sible that the STAT3-dependent effects on IL10 acti-
vation in primary cells might be related to promoter 
transactivation. Finally, STAT4, which is important 
for the differentiation of IFNγ- and IL-10-producing 
mouse TH1 cells72, was also reported to have a role in 
inducing IL-10 expression by mouse NK cells136. The 
molecular mechanisms underlying the participation of 
other STAT molecules in the control of IL-10 expres-
sion require further clarification, particularly as several 
STAT molecules are required for the differentiation of 
TH cell subsets and thus can modulate the induction 
of IL-10 in an indirect manner.
The list of transcription factors involved in the reg-
ulation of IL10 expression is expanding (FIG. 4), which 
reflects the degree of precision and complexity that the 
expression of this cytokine demands. The exact contri-
bution of many of the transcription factors discussed 
above remains elusive and may in some cases be cell spe-
cific, but may also depend on the type of stimulus that 
triggers IL10 expression or may affect IL10 expression 
indirectly. with the identification and characterization 
of distal regulatory regions in the IL10 locus, a role for 
other transcription factors might also be revealed.
Figure 4 | Transcription factors that control interleukin‑10 
expression by CD4+ T cells and antigen‑presenting cells. 
Many transcription factors have been found to regulate the 
expression of interleukin‑10 (IL‑10) both in antigen‑ 
presenting cells and in CD4+ T cells. Represented here are 
the signalling molecules (in the outer circle) and transcription 
factors (inner circle) involved in IL‑10 regulation with a role 
validated by promoter studies (mutagenesis or chromatin 
immunoprecipitation) or by studies in genetically modified 
mice. Part of these studies were carried out in cell lines, 
although recently the study of IL‑10 regulation has involved 
primary cells. Some of the indicated transcription factors are 
cell specific and others seem to have a wider role, as discussed 
in detail in the text. The transcription factors in bold are 
common to various cell types in regulating IL‑10 production. 
Transcription factors marked with * are those that have not 
been shown to bind the promoter or the Il10 locus. ATF1, 
activating transcription factor 1, C/EBPβ, CCAAT/enhancer 
binding protein‑β; CREB, cAMP‑responsive‑element‑binding 
protein; DC, dendritic cell; ERK, extracellular signal‑regulated 
kinase; GATA3, GATA binding protein 3; NF‑κB, nuclear 
factor‑κB; PBX1, pre‑B‑cell leukaemia transcription factor 1; 
PREP1, PBX‑regulating protein 1; SMAD4, mothers against 
decapentaplegic homologue 4; SP1, specific protein 1; STAT, 
signal transducer and activator of transcription; SYK, spleen 
tyrosine kinase; T
H
, T helper; TPL2, tumour progression locus 2.
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(TFH cell). A CD4
+ T cell that 
provides help to B cells in 
follicles and germinal centres. 
The TFH cell signature includes 
the expression of CXCR5, ICOs, 
CD40 ligand and IL-21, factors 
that mediate TFH cell homing to 
follicles and B cell help.
MicroRNAs 
single-stranded RNA 
molecules of approximately 
21–23 nucleotides in length 
that regulate the expression  
of other genes.
Silencing IL10 expression. Recent studies have provided 
evidence for the role of certain transcription factors in 
silencing Il10 expression. For example, it has been sug-
gested that the transcription factor eTS1 has a role in 
repressing the production of IL-10 by mouse TH1 cells, 
as eTS1-deficient TH1 cells show a marked increase in 
the production of this cytokine137. However, it is possible 
that the effect of eTS1 on IL-10 expression results from 
diminished TH1 cell differentiation, as no interaction of 
eTS1 with the Il10 locus has been shown. Similarly, an 
increase in IL-10 expression was observed in mice defi-
cient for the TH1 cell-specific transcription factor T-bet 
(also known as TBX21) that were infected with M. tuber-
culosis, suggesting that T-bet might have a role in the 
negative regulation of IL-10 expression by TH1 cells138. 
However, as IFNγ expression is also lost in the absence of 
T-bet, this effect on IL-10 could reflect a blockade of TH1 
cell differentiation, with the increase in IL-10 expression 
resulting from other cells. This notion is strongly sup-
ported by the observation that IL-10 production by TH1 
cells is accompanied by the expression of high levels of 
IFNγ and T-bet69,72.
Silencers of IL-10 expression have also been identi-
fied in cells of the innate immune response. MHC class II 
transactivator (CIITA) has been shown to negatively regu-
late the expression of IL-10 by mouse DCs and the activity 
of the Il10 promoter in a mouse macrophage cell line139. 
As mentioned above, it is also possible that STAT1 nega-
tively regulates IL-10 expression in human monocytes89,140. 
However, it is still unclear whether STAT1 directly or indi-
rectly affects the Il10 locus. In addition, isolated peritoneal 
macrophages from B cell lymphoma 3 (BCL-3)-deficient 
mice produce increased amounts of IL-10, suggesting that 
BCL-3 is an inhibitor of IL-10 expression in macrophages; 
although, again, it is questionable whether this effect is 
direct or indirect141. BCL-6 has been reported to have 
a role in inhibiting the production of TH2 cell-specific 
cytokines including IL-10 (ReF. 142), and in its absence 
T cells activated with strong co-stimulation show a large 
upregulation of Il4, Il10 and Il13 mRNA, whereas over-
expression of BCL-6 in wild-type T cells strongly inhibits 
the production of IL-10 following activation142. However, 
it is unknown whether BCL-6 directly regulates the Il10 
locus. In recent reports, BCL-6 was required for T follicular 
helper cell differentiation, but it inhibited the differen-
tiation of other TH cell subsets, by direct interaction with 
T-bet, GATA3 and retinoic acid receptor-related orphan 
receptor-γt (RoRγt)143–145. It is therefore possible that the 
previously reported BCL-6-mediated IL-10 suppression in 
TH2 cells142 is a consequence of the inhibition of the TH2 
cell differentiation pathways and therefore not due to a 
direct effect of BCL-6 on Il10 transcription. In support of 
this, no BCL-6 consensus binding sites have as yet been 
found in the Il10 promoter142.
The complexity of IL10 regulation by different 
cells of the immune system, having both positive and 
negative feedback loops, shows the tight control that 
is essential to achieve a balance between an effective 
immune response and immunopathology. This complex 
regulation ranges from common to distinct pathways of 
IL-10 induction in different cell types.
Mechanisms of post‑transcriptional regulation
Modulation of mRNA stability is an important compo-
nent in the regulation of expression of several cytokines 
(reviewed in ReF. 146) and most cytokine genes have a 
long 3ʹ untranslated region (uTR), containing class II 
adenosine–uridine-rich elements (ARe) that target 
mRNAs for rapid degradation. Multiple copies of poten-
tial mRNA destabilizing motifs are found in the 3ʹ uTR 
of Il10 mRNA147. various factors can alter the stability of 
Il10 mRNA, including IL-10 itself, which triggers Il10 
mRNA degradation148,149, and adenosine receptor activa-
tion, which acts by relieving the translational repressive 
effect of the Il10 3ʹ uTR thereby increasing the mRNA 
half-life and the amount of IL-10 produced150.
More recently, Il10 mRNA has been identified as a 
tristetraprolin (TTp) target in a wide genome screen151. 
TTp is a RNA-binding molecule that can induce rapid 
degradation of mRNA following binding to ARes in 
3ʹ uTRs. Supporting this finding, macrophages from 
TTp-deficient mice showed a decrease in the rate of 
Il10 mRNA decay and an increase in IL-10 secretion151. 
Moreover, activation of p38 has been reported to stabi-
lize the Il10 mRNA by inhibiting the action of TTp152. 
Interestingly, IL-10 induces TTp expression in a STAT3-
dependent manner, contributing to the establishment of 
an anti-inflammatory programme153.
Finally, a role for microRNAs in the regulation of IL-10 
expression has been described134. A recent report shows 
that the human microRNA miR-106a, expressed in cells 
of both lymphoid and myeloid origin, binds the 3ʹ uTR of 
the IL10 mRNA and induces its degradation154.
This level of post-transcriptional regulation of IL-10 
expression might explain why, despite the existence of 
common pathways for IL-10 induction, different cells ulti-
mately secrete different amounts of IL-10. Thus, in addi-
tion to genetic regulation, post-transcriptional regulation 
contributes to the fine tuning of IL-10 expression.
Conclusion and outstanding questions
owing to the key role of IL-10 in the immune response 
and the link between defective IL-10 production and 
certain autoimmune and inflammatory diseases, an 
understanding of the molecular mechanisms that regu-
late the expression of this cytokine is crucial.
The fact that various cell types can express IL-10 makes 
the subject of IL10 regulation challenging. It also high-
lights the complexity of this regulation. Several early stud-
ies on the molecular regulation of IL-10 reported apparent 
differences. The fact that cell lines and different conditions 
were used in most of these studies has certainly been a 
contributing factor to these discrepancies. Indeed, recent 
studies using primary T cells, macrophages and DCs show 
more consistent results between laboratories with respect 
to the regulation of IL10 expression.
Several general conclusions from these studies 
can be made: first, many cells of the innate and adap-
tive immune response produce IL-10 regardless of the 
stimulus. Second, different stimuli, or the strength of 
the stimulus, give rise to different levels of IL-10 in the 
same cell type. Third, some of the molecular mechanisms 
for the regulation of IL-10 differ according to the cell 
R E V I E W S
NATuRe RevIewS | Immunology  ADvANCe oNLINe puBLICATIoN | 9
© 20  Macmillan Publishers Limited. All rights reserved10
type, although common mechanisms also exist. And 
fourth, IL-10 is induced in many situations together with 
pro-inflammatory cytokines, although the pathways that 
induce IL-10 expression may actually negatively regulate 
the expression of these pro-inflammatory cytokines.
Several outstanding questions and future challenges 
remain. which cells are induced to produce IL-10 during 
an immune response to specific pathogens and gut flora, 
and which IL-10-producing cells are required to prevent 
host damage or to conversely inhibit immune responses, 
thereby contributing to chronic infection? what signal-
ling pathways and transcription factors can specifically 
induce IL-10 in different immune cells independently 
of the induction of pro-inflammatory cytokines? what 
signalling pathways are required in different cells, and 
what is the hierarchy of transcription factor binding to 
IL10 regulatory elements? Is IL-10 production in vivo 
dictated by the environment and inflammatory stim-
uli, and what maintains the remodelling of the IL10 
locus? For example, can TH1 cells detect signals and 
inflammatory molecules induced by microorganisms and 
their products in the microenvironment and turn on IL-10 
production and thus reduce tissue damage? Many of 
these questions will be answered by comparing the kinet-
ics and quantity of IL-10 expression and production in 
different immune cells stimulated with different stimuli 
and by elucidating the molecular signalling pathways 
leading to IL-10, by traditional biochemical methods, 
bioinformatics or high-throughput approaches, such as 
chromatin immunoprecipitation sequencing.
outstanding questions might be answered by dis-
secting the mechanisms that regulate the expression 
of IL-10 in different cells, during different immune 
responses to microorganisms and in different anatomical 
locations (for example, comparing IL-10 expression in 
the lungs to the blood during M. tuberculosis infection73). 
An understanding of how IL-10 expression is regulated 
during such immune responses undoubtedly will be of 
use in developing therapeutic strategies to target IL-10 
production in disease.
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Online summary
•	 Interleukin-10 (IL-10) is not a cell type-specific cytokine, but 
instead it is broadly expressed by many immune cells.
•	 Several layers of regulation regulate IL-10 production, includ-
ing changes in the chromatin structure, enhancement or silenc-
ing of IL10 transcription and post-transcriptional regulatory 
mechanisms.
•	 Many of the molecular events leading to IL10 expression are simi-
lar and common to various IL-10-producing immune cells, but cell 
type-specific signals also exist.
•	 Induction of IL-10 often occurs together with pro-inflammatory 
cytokines, although pathways that induce IL-10 may actually nega-
tively regulate these pro-inflammatory cytokines.
•	 understanding the specific molecular events that regulate the 
expression of IL-10 will be important for the design of new strate-
gies of immune intervention.
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The anti‑inflammatory cytokine interleukin‑10 (IL‑10) 
has a central role in limiting inflammatory responses 
to protect against excessive tissue damage. Recent 
evidence suggests that many types of immune cell can 
produce IL‑10, but how is its transcription regulated in 
these different cell types?
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